To date, no effective drugs have been developed to address cognitive dysfunction in schizophrenia. Here we will highlight the three main methodological challenges which may be contributing to these high failure rates, and propose potential practical solutions to these problems.
Cambridge Cognition and Boehringer Ingelheim have been investigating cognitive performance among patients with schizophrenia, with a view to improving future pro-cognitive drug trial designs. Our Director of Neuroscience, Dr Kiri Granger, presented the latest findings at ISCTM and SIRS.
Can acetylcholinesterase inhibitors and CNS stimulants tackle cognitive dysfunction in multiple scle
Cognitive dysfunction in multiple sclerosis (MS) presents a significant, unmet therapeutic need. Researchers at Cambridge Cognition and the University of Manchester investigated potential solutions to this problem with a systematic review and meta-analysis of pro-cognitive drug trials in MS.
The importance of recruiting patients for pro-cognitive drug trials in schizophrenia on the basis of cognitive dysfunction.
Introducing a blog-post series to discuss key limitations, and potential improvements, for pro-cognitive drug trials in schizophrenia.
When assessing cognitive function, tests that are reliable, time and cost efficient and are comparable across cultures and languages are the key to producing accurate and valid results. There are various cognitive assessment tools out there, but what are the benefits of using language and culture independent touchscreen tests such as CANTAB?